In the previous eight years, the CLINAM Summit grew to the largest in its field with 12 presenting Noble Laureates and more than 500 participants from academia, industry, regulatory authorities and policy from over 40 countries in Europe and worldwide.
With this success and broad support by well 31 renowned collaborating initiatives, the CLINAM‐Summit is today a most important marketplace for scientific exchange and discussions of clinical, regulatory, political and ethical aspects in this field of cutting‐edge medicine. EUNCL successfully presented during a dedicated session about its work, cooperation with US-NCL and regulators as well as how sponsors can access.
Introduction about EUNCL (PDF, 9.0 MB)
Patrick BOISSEAU, CEA-LETI, FR
How can EUNCL support industry (PDF, 1.0 MB)
Caroline LEMARCHAND, Onxeo (tbc), FR
EU-US cooperation on nanocharacterisation (PDF, 3.4 MB)
Jennifer GROSSMAN, NCI’s NCL, USA
Connecting EUNCL with regulators (PDF, 1.7 MB)
Susanne BREMER-HOFFMANN, EC-JRC, IT
The next frontiers in nanocharacterisation (PDF, 3.8 MB)
Sven Even BORGOS, SINTEF, NO
How can stakeholders access EUNCL? (PDF, 0.5 MB)
Simon BACONNIER, CEA-Clinatec, FR
European Nanomedicine Characterisation Laboratory (EUNCL)